Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to start receiving our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

Mavacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID), with a preferential action on the cyclooxygenase (COX)-2 isoform of COX and a long duration of action. It is classified chemically as a member of the sulphonamide subgroup of coxibs. Mavacoxib is highly lipid but very poorly water...

Author(s)
Lees, P.; Pelligand, L.; Elliott, J.; Toutain, P. L.; Michels, G.; Stegemann, M.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Journal of Veterinary Pharmacology and Therapeutics, 2015, 38, 1, pp 1-14
Abstract

Mavacoxib is a selective cyclooxygenase-2 nonsteroidal anti-inflammatory drug that has been used for management of osteoarthritis and other inflammatory conditions in dogs. The main advantage of mavacoxib over other nonsteroidal anti-inflammatory drugs is its longer plasma half-life, leading to...

Author(s)
Huckins, G. L.; Carpenter, J. W.; Dias, S.; Kukanich, B.
Publisher
American Association of Zoo Veterinarians, Pomona, USA
Citation
Journal of Zoo and Wildlife Medicine, 2020, 51, 1, pp 53-58
Abstract

A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a...

Author(s)
Payne-Johnson, M.; Becskei, C.; Chaudhry, Y.; Stegemann, M. R.
Publisher
BMJ Publishing Group, London, UK
Citation
Veterinary Record, 2015, 176, 11, pp 284
Abstract

The pharmacokinetics of mavacoxib were evaluated in an absolute bioavailability study, a dose-proportionality study and a multi-dose study in young healthy adult laboratory Beagle dogs and in a multi-dose safety study in Beagle-sized laboratory Mongrel dogs. When administered as the commercial...

Author(s)
Cox, S. R.; Lesman, S. P.; Boucher, J. F.; Krautmann, M. J.; Hummel, B. D.; Savides, M.; Marsh, S.; Fielder, A.; Stegemann, M. R.
Publisher
Blackwell Publishing Ltd, Oxford, UK
Citation
Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 5, pp 461-470
Abstract

The inducible inflammatory enzyme cyclooxygenase-2 (COX-2) and its product prostaglandin E2 (PGE2) are prominent tumour promoters, and expression of COX-2 is elevated in a number of tumours of both humans and canines. Targeting COX-2 in cancer is an attractive option because of readily available...

Author(s)
Hurst, E. A.; Pang, L. Y.; Argyle, D. J.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2019, 17, 2, pp 194-207
Abstract

Background: The NSAID mavacoxib (TrocoxcilTM) is a recently described selective COX-2 inhibitor used for the management of inflammatory disease in dogs. It has a long plasma half-life, requiring less frequent dosing and supporting increased owner compliance in treating their dogs. Although the use...

Author(s)
Pang, L. Y.; Argyle, S. A.; Kamida, A.; Morrison, K. O.; Argyle, D. J.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2014, 10, 184, pp (5 September 2014)
Abstract

Background: Pedobarographic analyses detect pressure redistribution among limbs and within limbs in humans, equids and dogs. The main objective of this study was to assess the usefulness of a set of pedobarographic parameters for the detection of lameness, as well as for its suitability for...

Author(s)
López, S.; Vilar, J. M.; Rubio, M.; Sopena, J. J.; Santana, A.; Rodríguez, O.; Rodríguez-Altonaga, J. A.; Carrillo, J. M.
Publisher
BioMed Central Ltd, London, UK
Citation
BMC Veterinary Research, 2019, 15, 193, pp (11 June 2019)
Abstract

Mavacoxib (TrocoxilTM) is an oral long-acting COX-2 inhibitor approved for the treatment of osteoarthritis in dogs. Two field trials were conducted in client-owned dogs suffering from osteoarthritis, with dosages of 4 mg/kg body weight (BW) (Study 1) or 2 mg/kg BW (Study 2). Mavacoxib plasma...

Author(s)
Cox, S. R.; Liao, S.; Payne-Johnson, M.; Zielinski, R. J.; Stegemann, M. R.
Publisher
Blackwell Publishing Ltd, Oxford, UK
Citation
Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 1, pp 1-11
Abstract

NSAIDs are the cornerstone of medical management of canine osteoarthritis (OA). Meloxicam is a daily-administered NSAID widely available in a liquid formulation and manufacturer's summary of product characteristics (SPC) advise that it is given at the lowest effective dose. Mavacoxib is a...

Author(s)
Walton, M. B.; Cowderoy, E. C.; Wustefeld-Janssens, B.; Lascelles, B. D. X.; Innes, J. F.
Publisher
BMJ Publishing Group, London, UK
Citation
Veterinary Record, 2014, 175, 11, pp 280
AbstractFull Text

The aim of this study was to assess the efficacy of mavacoxib, a cox-2 inhibitor, to improve the peak vertical force (PVF) and vertical impulse (VI) of lame client-owned dogs with severe coxofemoral osteoarthrosis (OA) by using a force platform. A group of ten canarian presa dogs with lameness and...

Author(s)
Vilar, J. M.; Morales, M.; Santana, A.; Batista, M.; Miró, F.; Spinella, G.
Publisher
Faculty of Veterinary Science, University of Agriculture, Faisalabad, Pakistan
Citation
Pakistan Veterinary Journal, 2013, 33, 2, pp 229-233

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics